Table 3.
Clinical characteristics of the training and test datasets.
| Overall | Training dataset | Test dataset | P value | |
|---|---|---|---|---|
| (N=131) | (N=93) | (N=38) | ||
| Age (year) | ||||
| Mean (SD) | 71.9 (7.66) | 71.3 (8.09) | 73.4 (6.34) | 0.152 |
| tPSA (ng/dL) | ||||
| Median [Q1, Q3] | 42.6 [14.2,124] | 43.5 [14.3,124] | 27.3 [13.8,94.0] | 0.505 |
| PI-RADS score | ||||
| 4 | 14 (10.7%) | 10 (10.8%) | 4 (10.5%) | >0.999 |
| 5 | 117 (89.3%) | 83 (89.2%) | 34 (89.5%) | |
| PCa location | ||||
| PZ and TZ | 115 (87.8%) | 84 (90.3%) | 31 (81.6%) | 0.297 |
| PZ only | 10 (7.6%) | 5 (5.4%) | 5 (13.2%) | |
| TZ only | 6 (4.6%) | 4 (4.3%) | 2 (5.3%) | |
| PCa volume (mm3) | ||||
| Median [Q1, Q3] | 10000 [2750,25100] | 12000 [2880,26400] | 6140 [2200,19400] | 0.373 |
| PCa ADC value (*10^-3 s/mm3) | ||||
| Mean (SD) | 791 (128) | 790 (124) | 793 (138) | 0.821 |
| ISUP | ||||
| 1 | 4 (3.1%) | 4 (4.3%) | 0 (0%) | 0.557 |
| 2 | 12 (9.2%) | 7 (7.5%) | 5 (13.2%) | |
| 3 | 20 (15.3%) | 15 (16.1%) | 5 (13.2%) | |
| 4 | 27 (20.6%) | 18 (19.4%) | 9 (23.7%) | |
| 5 | 68 (51.9%) | 49 (52.7%) | 19 (50.0%) | |
| Stage | ||||
| T3~4N0M0 | 62 (47.3%) | 43 (46.2%) | 19 (50.0%) | 0.316 |
| TxN1M0 | 20 (15.3%) | 17 (18.3%) | 3 (7.9%) | |
| TxNxM1 | 49 (37.4%) | 33 (35.5%) | 16 (42.1%) | |
| Treatment | ||||
| Radiotherapy | 4 (3.1%) | 1 (1.1%) | 3 (7.9%) | 0.104 |
| Hormonal therapy | 52 (39.7%) | 39 (41.9%) | 13 (34.2%) | |
| Comprehensive therapy | 75 (57.3%) | 53 (57.0%) | 22 (57.9%) | |
| Label | ||||
| BCR- | 100 (76.3%) | 70 (75.3%) | 30 (78.9%) | 0.824 |
| BCR+ | 31 (23.7%) | 23 (24.7%) | 8 (21.1%) | |